Compare CFND & ITRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CFND | ITRM |
|---|---|---|
| Founded | N/A | 2015 |
| Country | | Ireland |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.4M | 24.3M |
| IPO Year | 2025 | 2018 |
| Metric | CFND | ITRM |
|---|---|---|
| Price | $3.72 | $0.03 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9.00 |
| AVG Volume (30 Days) | 17.0K | ★ 46.5M |
| Earning Date | N/A | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.43 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $947.65 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $3.55 | $0.03 |
| 52 Week High | $9.67 | $1.42 |
| Indicator | CFND | ITRM |
|---|---|---|
| Relative Strength Index (RSI) | 45.07 | 26.10 |
| Support Level | $3.62 | N/A |
| Resistance Level | $4.15 | $0.39 |
| Average True Range (ATR) | 0.13 | 0.02 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 48.81 | 3.34 |
C1 Fund Inc is a non-diversified, closed-end management investment company designed to give investors access to the private digital asset ecosystem. Its investment objective is to maximize its portfolio's total return. The fund targets a handpicked portfolio of the late-stage private companies driving the future of digital asset services and technology. It offers early access to the next generation of category-defining companies and aims to bridge the gap between public and private markets and give investors access to the private companies with the safeguards of a NYSE listed fund that is regulated and liquid.
Iterum Therapeutics PLC is a pharmaceutical company dedicated to maximizing the commercial potential of Orlynvah, an oral-branded penem available in the United States and potentially the first and only oral and intravenous (IV) branded penem available globally. Its product Orlynvah has the potential to be a treatment for complicated urinary tract infections caused by the designated microorganisms, without the presence of known toxicities of some other antibiotics. The company operates in a single business segment, which is the development and commercialization of treatments for drug-resistant bacterial infections.